Axonics® reports third quarter 2020 results

Irvine, calif.--(business wire)--axonics modulation technologies, inc. (nasdaq: axnx), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (snm) devices for the treatment of urinary and bowel dysfunction, today reported results for the third quarter 2020. raymond w. cohen, ceo of axonics, said, "in the third quarter, despite headwinds from covid-19 and the launch of a rechargeable device by our competitor, we continued to add new custo
AXNX Ratings Summary
AXNX Quant Ranking